Radiation Oncology — Specialty Profile

Exploratory, not prescriptive. This profile blends hard data (pay, match rates, burnout, demographics — each sourced and dated) with generalizations and synthesized online opinion about culture and "who fits." It's here to help you get curious and go find out for yourself — not to tell you who to become. Numbers marked ⟳ verify change every year; check the linked source before you quote one. Last reviewed: 2026-07-25.

Also called: rad onc, RO. Entered through the Match (an intern year plus four years of radiation oncology). Organ system: all of them, because rad onc is organized around cancer wherever it appears, delivered through targeted radiation.

The 30-second version

Radiation oncology is the specialty that treats cancer with precisely targeted radiation, a field built at the intersection of oncology, medical physics, and imaging technology. You meet a patient at diagnosis, design a course of treatment that aims a beam at a tumor while sparing the healthy tissue millimeters away, walk them through weeks of daily treatment, and then follow them for years afterward. The work is cerebral and plannable, built on contours, dose distributions, and treatment planning, and it is almost entirely outpatient, with little overnight call. That combination of high pay, humane hours, and deep long-term cancer relationships is why rad onc is one of medicine's genuine "have it all" fields. The catch, and it's real, is a decade-long argument about the job market: a small, geographically clustered field buffeted by hypofractionation, AI, reimbursement cuts, and consolidation.1

Quick dashboard (details and sources below)
Training after med school 5 years (1 clinical/intern year + 4 rad onc)
Total from college start ~13 years (4 undergrad + 4 med school + 5 training)
Competitiveness Volatile — was very high, softened sharply, now recovering ⟳
Typical full-time pay ~$550,000–$590,000 total comp ⟳
Pay range (structure) 10th ~$495k · median ~$585k · 90th ~$640k (SalaryDr panel, n=42) ⟳
Lifestyle Outpatient, scheduled, minimal call — one of the best in medicine
Burnout Toward the lower end; often folded into "oncology" (~49–53%) ⟳
% women ~27% practicing (2016 baseline; higher now) · 37.5% of residents ⟳
DO / IMG accessibility 2026 PGY-2, of 167 filled: DO 10.8% and rising; IMG 10.8% and falling ⟳

What they actually do

Radiation oncologists treat cancer using ionizing radiation: as a curative treatment, as part of combined therapy with surgery and chemotherapy, and for palliation. The core work is a sequence: a consultation to decide whether and how to irradiate; a simulation (imaging the patient in the exact position they'll be treated in); treatment planning, the intellectual heart of the field, where physician, medical physicist, and dosimetrist design a plan that delivers a lethal dose to the tumor while keeping nearby organs-at-risk under their tolerance; then on-treatment visits managing side effects across a multi-week course; and follow-up for years afterward.2 The defining skill is the fusion of cancer biology, anatomy, imaging, and physics into a dose plan, and the judgment to know when radiation helps and when it doesn't, rather than any procedure.

The work is team-dense in an unusual way. Rad oncs work daily alongside medical physicists, dosimetrists, radiation therapists, oncology nurses, and navigators, roles almost unique to this specialty, running what one physician calls "an orchestra."2 The care is longitudinal: you build deep bonds with patients across a cancer course and often for decades of follow-up, without the ward chaos of inpatient medicine.2

Representative work and modalities: external beam radiation therapy (EBRT) · intensity-modulated radiation therapy (IMRT) · stereotactic radiosurgery and stereotactic body radiotherapy (SRS/SBRT) · brachytherapy (implanted/internal radiation sources) · proton/particle therapy · treatment planning and dosimetry review · management of radiation toxicities · urgent treatment of oncologic emergencies (spinal cord compression, uncontrolled bleeding).12

A day in the life: Scheduled and outpatient. A morning of new-patient consults and follow-ups, time at the planning workstation refining contours and reviewing dose distributions with physics and dosimetry, on-treatment visits with patients partway through their course, and a tumor board or multidisciplinary conference. Emergencies are the exception rather than the rhythm. An oncologic emergency can demand urgent same-day treatment, but call is typically light and phone-based.2 The calendar is largely knowable in advance, which is exactly the draw for people who want to protect evenings and weekends.

The training path & time to completion

Medical school (4 yrs) → 1 clinical/intern year (PGY-1) → radiation oncology residency (4 yrs, PGY-2–PGY-5) → board-eligible with ABR.3 Radiation oncology positions in the Match are almost all offered at the PGY-2 (advanced) level, so applicants match separately into a PGY-1 year (a transitional year, or a categorical/prelim year in internal medicine or surgery) and into the advanced rad onc program.3

  • Board: the American Board of Radiology (ABR). Certification requires passing the Qualifying (written) exams, with distinct components in Radiation and Cancer Biology, Medical Physics, and Clinical Radiation Oncology, followed by a Certifying (oral) exam. That dedicated physics and radiobiology exam burden is a defining feature no other clinical specialty shares.3 ⟳
  • A small, research-heavy field. Seventy-nine programs participated in the 2026 Match, against 81 in 2025; FREIDA lists ~89 accredited programs and ~715 total residents (~8.3/program), one of the smallest physician specialties by program and resident count.3 Clinical training integrates medical physics, treatment planning, dosimetry, and radiobiology alongside oncologic care.3
  • No fellowship required to practice. Rad onc is a primary specialty entered directly through the Match; fellowship is optional. Most practice as generalists but develop a disease-site focus (see Subspecialties).1
  • Total from the start of college: ~13 years (4 + 4 + 5).

How competitive is it? (the swing you need to know)

Radiation oncology is one of the most dramatic competitiveness stories in modern medical training, and exactly the kind of hidden context a premed would never pick up from a list.

The field went from one of the most competitive specialties (2000s through the mid-2010s) to a field with large numbers of unfilled positions (peaking 2019–2023), driven largely by job-market and workforce fears: oversupply concerns, hypofractionation reducing treatment volumes, and consolidation. It has since recovered sharply, and commentators now debate whether the field has reached a "new steady state."41

  • Unfilled PGY-2 positions collapsed: 34 (2023) → 12 (2024) → 5 (2025) → 4 (2026). A ~60% drop from 2024 to 2025, and the recovery has held for a second cycle.456 ⟳
  • 2026 Match: 79 programs, 171 PGY-2 positions offered, 167 filled (97.7% fill rate), after 97.2% in 2025 and 93.1% in 2024.576 ⟳
  • Not oversubscribed the way peak-competitive fields are: 247 applicants ranked the specialty against 171 PGY-2 positions (1.44 per position), of whom 157 were US MD seniors — 0.92 per position. That is why DO and IMG applicants fill a meaningful minority.6 ⟳
  • Matched US-MD seniors are academically strong: mean USMLE Step 2 CK ≈ 250 (an aggregator cites 249), 97.5% match rate, and, as the field's signature, a mean of 15.9 abstracts, presentations, and publications and 4.2 research experiences, among the highest of any specialty.2 ⟳

The honest read: rad onc is reachable right now in a way it wasn't a decade ago, but the same workforce anxiety that opened the door is the field's defining controversy (see Compensation and the FLI angle). Note also that Step 1 is now Pass/Fail, so Step 2 CK and research productivity carry even more weight in an already research-heavy field.2

Compensation — the robust version

Rad onc sits in the upper tier of physician pay , typically top 7–10 of all specialties, but it is also one of the specialties most stressed by reimbursement cuts and a contentious job market, and that tension colors everything below.8 A note on sources first: surveys disagree because they measure different things and because rad onc is small (small samples, and Medscape bundles it into "oncology"). Treat Doximity 2025 and SalaryDr 2026 as the best anchors for magnitude, and read the structure numbers as directional.89

National number. The two most recent robust sources cluster near $585K–$593K: Doximity 2025 reports $588,678 average total comp (7th highest of all specialties), and SalaryDr 2026 reports a $585,000 median / $592,885 average (though on a small self-reported sample, n=42).89 Older/recruiting surveys run lower (MGMA 2022 ~$477,807; AMGA 2022 ~$449,891; Merritt Hawkins ~$423,233, starting-skewed). A defensible mid-2026 "typical full-time" figure is ~$550,000–$590,000 total compensation.8910 ⟳

The spread (structure, from SalaryDr 2026, on a small and indicative n): 10th pct $495,000 · 25th $550,000 · median $585,000 · 75th $620,000 · 90th $640,000, with a reported range up to $1,635,000 (top outlier likely a practice-owner/partner). Base salary is ~89% of total; median bonus ~$70,000; 86% receive some incentive comp.9 Broad aggregators (Salary.com, Payscale, ZipRecruiter) skew low vs. survey data and should be treated cautiously.10 ⟳

Experience matters more than in EM. SalaryDr 2026: early-career (0–5 yrs) ~$521,209 against experienced (10+ yrs) ~$658,045, about 26% higher with tenure, as productivity and partnership ramp.9 ⟳

Setting is the biggest single lever, and academic pays the least. SalaryDr 2026 (small n per bucket): Private practice ~$669,000 · Large health system ~$595,000 · Hospital-employed ~$579,287 · Academic ~$526,111, so private practice carries a ~$143K premium over academic, about 27% higher.9 ⟳ Historically the single biggest wealth lever was freestanding-center ownership: owning the technical/facility component (the linacs and treatment delivery) captured the high technical reimbursement, letting physician-owners far outearn employed peers. That lever is being eroded by site-neutral payment pressure, consolidation of independents into hospital systems, and technical-fee cuts.11

Geography, where jobs and pay both cluster inversely to desirability. This is rad onc's structural signature: persistent oversupply in desirable urban/coastal metros (many trainees competing for few academic/urban slots, often at lower pay) and undersupply in rural areas (fewer physicians, but jobs that pay more and are harder to fill).11

  • By state (ZipRecruiter, aggregator, low confidence): highest are Alaska ~$401,826 · Oregon ~$401,557 · North Dakota ~$400,076, and note the rural, hard-to-fill states topping the list; lowest are Arkansas ~$299,275 · Georgia ~$283,629 · Florida ~$251,014.10 ⟳
  • By region (MGMA 2022, dated): Southern US ~$425,000 (highest) · Midwest ~$340,000 · West ~$328,000 (the reported ~$123,000 Eastern figure is almost certainly a data artifact; do not use it).10 ⟳
  • Note on SalaryDr metro tiles (e.g., LA ~$380K, Boston ~$370K, Miami ~$360K): these sit far below its own national median and appear internally inconsistent; do not rely on them.9

Employment models. Hospital-employed is the largest bucket (salary + wRVU productivity incentives), and it is largely insulated from the 2026 payer disruption because of facility billing structures. Private practice and freestanding centers have the highest ceiling via technical-component ownership and partnership, but are the most exposed to reimbursement cuts. Academic pays the least cash. Productivity (wRVU) models are structurally pressured because hypofractionation lowers the number of billable fractions per patient.11 The market is also consolidating fast: 2015–2023 saw practicing rad oncs +16%, large practices +51%, solo practices −27%, and total practice count −13%, shrinking the independent and partnership pathway.11

The reimbursement headwind that colors all of it. This is where rad onc's pay picture diverges sharply from most high-paying fields: the trend line points down on key codes:

  • Long-run Medicare cuts: IMRT treatment-delivery reimbursement fell ~39% (2010–2019); planning fell ~31% over the same period. ASTRO describes "decade-long declines in Medicare payments."1112
  • The 2026 coding shock (acute, ongoing): In Jan 2026 the AMA consolidated radiation treatment-delivery CPT codes into three tiers; Medicare repriced appropriately but commercial payers largely failed to update their fee schedules. An ASTRO survey (Apr 2026) found two-thirds of physicians reporting reimbursement cuts of ≥10%, with some regions seeing Q1 2026 revenue declines of 30–40%. Independent/freestanding and rural clinics are most at risk of closure; hospital-based systems are largely insulated.13
  • The policy bet, ROCR. The bipartisan Radiation Oncology Case Rate (ROCR) Value-Based Program Act (S.1031 / H.R.2120, 119th Congress) would shift payment from per-fraction to per-patient (episode-based), apply site-neutral rates across settings, and tie updates to medical inflation, designed to stabilize payments and blunt the hypofractionation revenue penalty. (Its predecessor, CMS's mandatory RO Model, was repeatedly delayed and never implemented.)1214 ⟳

Lifestyle — one of medicine's best

The single most-cited pro of rad onc: a controllable, almost entirely outpatient schedule with minimal call. Practicing radiation oncologists report roughly 45–50 hours/week (SalaryDr ~49), and because radiation courses are scheduled and plannable, the calendar is largely knowable in advance, a real draw for anyone protecting evenings, weekends, and family time.115

  • Outpatient and scheduled: consults, simulation, planning, on-treatment visits, and follow-ups, with little of the unpredictability that defines surgery, OB, or EM.15
  • Minimal call: overnight and true emergency call is uncommon; oncologic emergencies exist but are the exception. Call is typically light and phone-based.15
  • The one lifestyle trade-off is continuity rather than chaos. Because you follow patients through a multi-week course and for years afterward, some physicians feel tethered to being physically present for their patients over time (Dr. Sheila Rege describes trading some scheduling flexibility to keep long-term relationships intact).2

Lifestyle rating: 4/5. High schedule predictability and control, low call, outpatient rhythm; the main cost is the continuity tether, not unpredictable hours.

Wellbeing — good daily life, one distinctive stressor

Burnout: toward the lower end, with a real data caveat. Medscape frequently folds radiation oncology into a broad "oncology" category (which ran ~49–53% in 2024) and does not always break rad onc out separately. Where it is measured on its own, it tends to look better than the all-physician average (~49% in Medscape 2024), aided by controllable hours and low call. Treat this as directional rather than a precise rank.1516 ⟳

Satisfaction reads high, but the numbers that circulate for it do not hold up. This page carried ~90% would-choose-again and a 3.9-out-of-5 satisfaction rating from a crowdsourced panel of 42 people, for a specialty of roughly 5,400 active physicians. Nobody has published a would-choose-again rate by specialty since about 2019, so there is no figure to give here and none is asserted. The intrinsic rewards people describe — meaningful cancer care, intellectual depth, and the lifestyle — are consistently reported; the percentages attached to them were not measurements.15

Career longevity: strong. Controllable hours, minimal call, strong pay, and cognitively engaging (not physically punishing) work support long careers with lower physical wear than proceduralist fields; physicians commonly practice into their 60s.15

The signature stressor is JOB-MARKET ANXIETY, and it deserves to be named separately from ordinary burnout. Because the field is small (a few hundred graduates a year) and jobs cluster in specific systems and metros, trainees and junior attendings carry unusual anxiety about whether a good job will exist where they want to live. The contributing worries combine into a chronic, structural stressor: hypofractionation cutting revenue per patient, AI-assisted contouring and planning potentially reducing staffing needs, reimbursement cuts from the 2026 CPT revisions, and hospital consolidation reducing the number of employers. It doesn't come from the daily work being crushing (it isn't); it comes from uncertainty about the field's trajectory and about geographic flexibility.115

Who's in the field (demographics)

  • Women: ~27.1% of active radiation oncologists in the AAMC's 2016 baseline (3,533 men and 1,312 women), below the all-specialty average of ~38%, though the current share is likely somewhat higher. ASTRO membership runs ~33% female; its 2024 member survey respondents were 29% female. Residents are 37.5% women in AY2024-25, up from ~31% in a ~2018–19 cohort study, a rise of roughly a point a year that the study's own trend line predicted. Full-time female academic faculty ~30%.171819 ⟳
  • DO: a small but growing minority, with US DO seniors filling 10.8% of PGY-2 positions in 2026 (18 of 167 filled), after 8.6% in 2025 (15 of 174) and 8.0% in 2024. Historically rated "not friendly" to DOs, and the door has opened as the field softened.57620 ⟳
  • IMG: 10.8% in 2026 (2 US-citizen IMGs and 16 non-US IMGs of 167 filled), down sharply from 16.7% in 2025 (6 and 23 of 174) and 15.3% in 2024. The trend is worth more than either year: the DO share has run 8.0% → 8.6% → 10.8% while the IMG share has run 15.3% → 16.7% → 10.8%, so as US MD seniors returned to the field they displaced international graduates rather than osteopathic ones.576 ⟳
  • URiM: no clean, current specialty-specific figure was found in primary tables. The 2024 ASTRO survey reported White as the predominant race followed by Asian, with ~20% of respondents identifying as Hispanic/Latino/Spanish origin (survey respondents, not the full workforce). A specialty-collaboration paper has flagged URiM underrepresentation and concern about the impact of ending affirmative action on the pipeline. Precise URiM percentages are limited data; verify against AAMC Diversity in Medicine or ACGME.1821 ⟳

Culture, personality & the online stereotypes

Who gravitates here: cerebral, precise people who enjoy detail, planning, and getting contours and dose distributions exactly right; those drawn to the physics/technology-plus-oncology intersection and comfortable with quantitative reasoning; people who want relationships within a defined arc, meaning deep bonds across a cancer course and decades of follow-up without ward chaos; research-minded, academically inclined types; and team-based collaborators who like running care "like an orchestra" with physicists, dosimetrists, and therapists. As always, plenty of people in the field do not fit any single mold.21

The stereotypes. Community caricatures rather than facts, each with an unfair edge:

  • "The smartest people in medicine / the physics nerds." A flattering stereotype rooted in the field's quantitative demands and historically high board scores. Unfair edge: it caricatures rad oncs as aloof or purely technical and underplays that the job is deeply patient-facing and emotionally demanding. You walk people through cancer.
  • "Great lifestyle and pay, but no jobs." The most persistent modern stereotype. Unfair edge: it flattens a genuinely contested, evolving picture into a slogan. The job market is real, but its severity is disputed and has been improving on some metrics.
  • "A dying field: AI and hypofractionation are shrinking it." A doom stereotype. Unfair edge: radiation remains a cornerstone of cancer treatment benefiting a large share of patients, cancer incidence is rising with an aging population, and ASTRO's own modeling projects rough supply/demand balance through 2030. "Dying" overstates a real but bounded set of pressures.
  • "Strangers in the basement." The literal-and-figurative jab that rad oncs are invisible, tucked away by the linacs, overshadowed by "the oncologist" (meaning medical oncology). Rad oncs push back hard on this.22

What people say online (synthesized and paraphrased, not quotes): Across trainee and physician forums, the workforce/job-market controversy dominates discussion far more than daily-work complaints. Recurring themes: fear that desirable metros are saturated; advice that new grads may need to relocate, do locums, or accept a less-ideal first job; debate over whether income erodes 10–15% over five years as reimbursement and volumes shift. There's a persistent contrarian-versus-optimist split. Pessimists cite supply outpacing cancer-incidence growth, hypofractionation, and consolidation; optimists counter that the Match has recovered, ASTRO projects balance, and the pessimism itself has become self-correcting by scaring off applicants. Med-student threads frame it as a "high risk, high reward" gamble: everyone agrees the day-to-day life is excellent, and the disagreement is entirely about the five-to-ten-year outlook and where you'll be able to work. Notably, practicing attendings on forums are frequently more sanguine than anxious students. The consensus advice: shadow early (exposure is limited in med school), pick programs thoughtfully, get realistic mentorship, and go in clear-eyed about relocation.1

Voices from the field. Paraphrased from public writing, with links to the originals:

  • Dr. Sheila Rege, in the AMA's "Shadowing Dr." specialty profile, emphasizes strong work-life balance because emergencies are rare, describes the field as team-based "like an orchestra," and frames the core reward as deep, decades-long relationships with cancer patients, noting a good fit needs strong math and physics plus excellent bedside manner, empathy, patience, and emotional resilience.2
  • Mudit Chowdhary, a rad onc resident writing for KevinMD, argues rad oncs are central to cancer care, since radiotherapy benefits a large share of cancer patients, yet remain under-recognized, and calls on the field to raise its visibility through teaching and outreach ("aren't just strangers in the basement").22
  • Simul Parikh, the leading contrarian workforce/economics voice (Radiation Medicine: Dollars and Sense), argues supply grew ~16% (2015–2023) while cancer incidence rose only ~4%, and that hypofractionation and reimbursement cuts point to a projected ~10–15% real income decline over five years, while still encouraging qualified candidates to enter for the intrinsic rewards.23
  • ASTRO leadership (Dr. Neha Vapiwala), via Oncology News Central, attributes the 2025 Match recovery partly to more students rotating through the field, cautions it's too early to call a durable trend, and characterizes the specialty as robust and able to meet demand.4

The job-market debate, presented evenhandedly

This is the one thing to understand before choosing rad onc, so here it is straight:

  • The bear case (Parikh and forum pessimists): rad onc supply grew ~16% (2015–2023) while cancer incidence rose only ~4%, meaning fewer patients per physician, and combined with hypofractionation, the 2026 reimbursement revisions, and consolidation, this argues for a ~10–15% real income decline over five years.2311
  • The balanced/bull case (ASTRO Workforce analyses, Red Journal): ASTRO's modeling projects rough supply–demand balance through ~2030, with growth in the Medicare-eligible cancer population offsetting rising physician numbers; hypofractionation and loss of indications had only moderate modeling effects. ASTRO notes some scenarios show over- or under-supply and urges ongoing monitoring.24
  • The trend data (Match): unfilled PGY-2 spots fell ~34 (2023) → ~12 (2024) → ~5 (2025) → 4 (2026), and US MD seniors matching in rose meaningfully in 2025, which ASTRO frames as evidence of stabilization. Competitiveness has been volatile: a 2010–2016 boom, a 2019–2022 slump with unfilled spots, and a partial recovery since.45
  • Bottom line: the field is not collapsing, but it is geographically constrained and financially pressured, and reasonable, informed people disagree about how much. The daily life is excellent; the uncertainty is about the market, not the work.1

Why people choose it / why people leave

Why choose it: excellent, controllable, outpatient lifestyle with minimal call, which is rare among high-paying fields · high compensation (~$550K–$590K) for those hours · intellectually rich (physics + technology + oncology + treatment planning) · deep, meaningful, long-arc relationships with cancer patients · team-based, collegial, lower-chaos environment · low physical wear supports career longevity · lower-than-average burnout · no fellowship required.19

Why leave or avoid it: the job market, meaning a small field, geographically clustered jobs, and a real risk the ideal location won't have an opening · structural headwinds (hypofractionation, AI-assisted planning, reimbursement cuts, consolidation) with a credible-if-disputed case for gradual income erosion · limited med-school exposure means many discover it late · chronic uncertainty itself is a stressor · if you crave hands-on procedures or acute, high-adrenaline work, the pace can feel slow.111

Best fit if: you love the physics/technology-plus-oncology intersection and precise, plannable work · you want strong lifestyle and pay without sacrificing meaningful long-term patient relationships · you're research-minded and academically inclined · you have geographic flexibility and can relocate for the right job (this de-risks the biggest downside) · you're comfortable making a long-term bet on a contested-but-not-catastrophic outlook.1

Not for you if: you're geographically locked to a specific city or region and can't move, the single biggest structural risk · you need certainty about your field's 10-year trajectory and find open-ended workforce debate corrosive · you want procedural/surgical hands-on work or acute-care intensity · you dislike heavy quantitative/technical reasoning.1

The FLI angle — Radiation Oncology for first-gen, low-income & immigrant students

The genuine draw. For an FLI student, rad onc packages three things that matter a lot: high, stable income (life-changing for someone supporting family or repaying loans), an excellent, controllable lifestyle (protecting health and family/caregiving obligations in a way surgery or EM cannot), and deeply meaningful work guiding patients through cancer. The plannable, low-call schedule is especially valuable if you carry caregiving responsibilities.1

Two honest risks to name squarely:

  1. The geographically constrained job market is a real, FLI-specific risk. The single biggest de-risker in this field is the ability to relocate freely for the best job, and that's precisely the lever this field asks you to pull. An FLI graduate who needs to stay near family, a working spouse, a support network, or a specific immigrant community has less of that flexibility. The lifestyle-and-pay upside is real, but it is partly conditional on mobility that not everyone has. Name this to yourself honestly before committing.1

  2. The research-heavy application favors well-resourced applicants. Rad onc's residency application is unusually research-intensive, with the mean of 15.9 abstracts and publications among matched applicants, often a dedicated research year, strong mentorship, and home-program connections.2 Applicants from well-funded undergrad/med-school environments with built-in research infrastructure and mentor networks have a structural head start. An FLI applicant can absolutely compete, but should plan early and deliberately, leaning on formal summer research programs, away rotations, and mentorship pipelines to level the field rather than discovering the research bar late.

Bottom line: rad onc can be an outstanding fit for an FLI student, with high pay, humane hours, and meaningful work, if you either have geographic flexibility or go in clear-eyed about that constraint, and if you build the research/mentorship scaffolding early rather than late. The two things that most de-risk this field are the two things FLI students are most likely to lack by default; that's not a reason to avoid it, but it is a reason to plan around it deliberately.

Subspecialties & disease-site focus (also: how you specialize)

No fellowship is required to practice, and FREIDA notes no formally recognized ACGME fellowships, and subspecialization happens mostly within specific cancer types, built through practice pattern and institutional need rather than a mandatory credential.13

  • Disease-site focus (the main way rad oncs "specialize"): CNS/neuro · GU/prostate · GI · breast · head-and-neck · thoracic/lung · gynecologic · lymphoma · pediatric.1
  • Brachytherapy. Implanted/internal radiation-source expertise.
  • Pediatric radiation oncology. Treating childhood cancers, often at academic centers.
  • Proton / particle therapy. A growing, technology-intensive modality.
  • Stereotactic radiosurgery (SRS/SBRT). High-dose, highly conformal treatment focus.
  • Radiation oncology physics / research. Academic and technical development tracks.

Academic centers particularly value deep disease-site expertise.1

Fun facts

  • Radiation oncology is one of the smallest specialties by number, only a few hundred residency graduates a year, which is exactly why local job availability swings so much.1
  • It's a hybrid discipline built on medical physics: rad oncs work daily alongside medical physicists and dosimetrists, roles almost unique to this specialty.1
  • Hypofractionation, delivering the same or better outcomes in fewer, larger treatment sessions, is simultaneously a win for patients through fewer visits and a threat to revenue models, which is why it sits at the center of the field's economics debate.1
  • Radiotherapy is estimated to benefit a majority of cancer patients at some point, yet the specialty fights a persistent "invisible, in the basement" image problem.122
  • The residency Match went from unfilled spots (a shock for a once-hypercompetitive field) to a strong recovery within a few years, one of the more dramatic competitiveness swings in modern GME.41
  • Board scores and academic pedigree in rad onc have historically been among the highest in medicine, feeding the "smartest people in medicine" stereotype.21

Sources

Footnotes

  1. Radiation oncology lifestyle, wellbeing, culture, job-market debate, subspecialties, and FLI synthesis (compiled mid-2026), drawing on Medscape, ASTRO/Red Journal, KevinMD, AMA, and paraphrased forum sentiment. Includes hours/week, controllable-schedule and call profile, would-choose-again, workforce debate, and stereotypes. (Internal research digest, 2026; primary sources cited individually below.) ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21 ↩22 ↩23 ↩24

  2. NRMP, Charting Outcomes in the Match: U.S. MD Seniors, 2024 (2024) — matched rad onc: mean Step 2 CK 250 (aggregator 249), 97.5% match rate, mean 4.2 research experiences, mean 15.9 abstracts/presentations/publications, mean 16 contiguous ranks. https://www.nrmp.org/wp-content/uploads/2024/08/Charting_Outcomes_MD_Seniors_2024-2.pdf . Practice character, team ("orchestra"), continuity, and who-fits from AMA, "What it's like to specialize in radiation oncology: Shadowing Dr. Rege": https://www.ama-assn.org/medical-students/preparing-residency/what-it-s-specialize-radiation-oncology-shadowing-dr-rege ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12

  3. Radiation oncology training structure (5 yrs: 1 clinical PGY-1 + 4 rad onc PGY-2–5; advanced/PGY-2 Match), board (ABR — Radiation & Cancer Biology, Medical Physics, Clinical exams + oral Certifying exam), and program/resident counts (~81 Match / ~89 accredited; ~715 residents). NRMP Results and Data 2025 (https://www.nrmp.org/wp-content/uploads/2025/05/Main_Match_Results_and_Data_20250529_FINAL.pdf); ABR Radiation Oncology certification (https://www.theabr.org/radiation-oncology, accessed 2026, exam-day specifics ⟳); FREIDA/AMA (https://freida.ama-assn.org/specialty/radiation-oncology, accessed 2026). ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  4. Competitiveness swing and 2025 Match recovery; unfilled PGY-2 34→12→5 (2023→24→25); Vapiwala commentary. Oncology News Central, "Match Day Numbers Show 'Promising' Change in Radiation Oncology" (2025) (https://www.oncologynewscentral.com/oncology/match-day-numbers-show-promising-change-in-radiation-oncology); Practical Radiation Oncology, "The Radiation Oncology Match in 2025: A New Steady-State?" (2025) (https://www.practicalradonc.org/article/S1879-8500(25)00103-1/abstract). ↩ ↩2 ↩3 ↩4 ↩5

  5. NRMP, Results and Data: 2025 Main Residency Match (2025) — rad onc PGY-2: 81 programs, 179 offered, 174 filled (≈97.2%), 5 unfilled; 240 applicants ranked; US MD 126 / US DO 15 / US-citizen IMG 6 / non-US IMG 23 (minor sub-category split ⟳). https://www.nrmp.org/wp-content/uploads/2025/05/Main_Match_Results_and_Data_20250529_FINAL.pdf ; NRMP Advance Data Tables 2025: https://www.nrmp.org/wp-content/uploads/2025/03/Advance_Data_Tables_2025.pdf ↩ ↩2 ↩3 ↩4 ↩5

  6. NRMP, Results and Data: 2026 Main Residency Match (May 2026), Tables 1A and 2 — rad onc PGY-2: 79 programs, 171 offered, 167 filled (97.7%), 4 unfilled; 247 applicants ranked it, 157 of them US MD seniors. Of the 167 filled, US MD seniors 76.6%, MD graduates 1.8%, DO seniors 10.8%, US IMG 1.2%, non-US IMG 9.6%. A further 12 PGY-1 and 4 physician positions were offered and all filled. https://www.nrmp.org/wp-content/uploads/2026/05/Main_Match_Results_and_Data-2026.pdf Corrected 2026-08-17: the 2026 cycle reached this footnote and stopped there. The Quick dashboard carried an undated "DO limited (~9%); IMG a meaningful minority (~16–17%)" and the demographics bullets ran to 2025, so a reader took the older cycle as current on both axes — and the IMG share had nearly halved in the meantime. Both surfaces now carry 2026 with the year and the denominator stated, and the 2024 and 2025 figures stay as the trend. Corrected 2026-08-17: the unfilled-positions series that carries this page's recovery argument stopped one cycle short at "34 (2023) → 12 (2024) → 5 (2025)," in the competitiveness bullet and again in the job-market section, while the missing cycle sat three lines away in this footnote. It now runs 34 → 12 → 5 → 4 in both places, which strengthens the argument rather than changing it. The Match program count in the training section was likewise the 2025 figure with no year on it, against 79 in 2026; it now names its year. ↩ ↩2 ↩3 ↩4 ↩5

  7. NRMP, Results and Data: 2024 Main Residency Match (2024) — rad onc PGY-2: 80 programs, 175 offered, 163 filled (≈93.1%), 12 unfilled; US MD 114 / US DO 13 / US-citizen IMG 6 / non-US IMG 19. https://www.nrmp.org/wp-content/uploads/2024/06/2024-Main-Match-Results-and-Data-Final.pdf ↩ ↩2 ↩3

  8. Doximity 2025 Physician Compensation Report (2024 data) — rad onc avg total comp $588,678, 7th highest of all specialties. https://www.doximity.com/reports/physician-compensation-report/2025 ↩ ↩2 ↩3 ↩4

  9. SalaryDr, Radiation Oncology (self-reported, updated Jul 2026, n=42 — small sample) — median $585,000 / avg $592,885; percentiles 10th $495k · 25th $550k · median $585k · 75th $620k · 90th $640k (range to $1,635,000); base ~89% of total, median bonus ~$70k; early-career ~$521,209 vs 10+ yrs ~$658,045; by setting private $669k / large health system $595k / hospital-employed $579,287 / academic $526,111; ~49 hrs/week. The same page reports ~90% would choose again and satisfaction ~3.9/5; this page declines to use either figure and says so in the Wellbeing section, because nobody has published a would-choose-again rate by specialty since about 2019 and a 42-person crowd panel is not that publication. Corrected 2026-08-17: those two figures were listed here without that qualification, so a reader who followed the Wellbeing section's retraction down to the footnote found the numbers anyway. ⟳ https://www.salarydr.com/specialty/radiation-oncology ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8

  10. Physicians Thrive, "The Average Radiation Oncology Salary" (compiles MGMA/AMGA/Merritt Hawkins/ZipRecruiter/aggregators, mostly 2022–2023) — MGMA ~$477,807, AMGA ~$449,891, Merritt Hawkins ~$423,233; state highs Alaska/Oregon/North Dakota ~$400k, lows Arkansas/Georgia/Florida; region MGMA 2022 (South ~$425k highest); aggregator averages skew low. ⟳ https://physiciansthrive.com/physician-compensation/radiation-oncology-salary/ ↩ ↩2 ↩3 ↩4

  11. MDLinx, "IMRT, AI, and fewer cases: Is radiation oncology facing oversupply?" (2025) — freestanding-ownership lever and its erosion; practice-structure shift 2015–2023 (rad oncs +16%, large practices +51%, solo −27%, total practices −13%); IMRT Medicare cuts (delivery −39%, planning −31%, 2010–2019); hypofractionation ~halving fractions; geographic mismatch framing. https://www.mdlinx.com/article/imrt-ai-and-fewer-cases-is-radiation-oncology-facing-oversupply/4lSsrsJ0sKtBU3AKZc8hqI ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  12. ASTRO, Radiation Oncology Case Rate (ROCR) program and "decade-long declines in Medicare payments." https://www.astro.org/advocacy/key-issues-8f3e5a3b76643265ee93287d79c4fc40/rocr ; ASTRO ROCR Act 2025 press release: https://www.astro.org/news-and-publications/news-and-media-center/news-releases/2025/rocr-act-2025-press-release ↩ ↩2

  13. AJMC, "Payers Fail to Reset Radiation Oncology Payments to Match Coding Changes, and Some Clinics May Close" (2026) — Jan 2026 CPT consolidation; commercial payers failed to reprice; ASTRO Apr 2026 survey (two-thirds ≥10% cuts; Q1 revenue −30–40% in some regions); independent/rural clinics most at risk, hospital-based insulated. https://www.ajmc.com/view/payers-fail-to-reset-radiation-oncology-payments-to-match-coding-changes-and-some-clinics-may-close-leading-oncologist-says ↩

  14. Congress.gov, S.1031 — ROCR Value Based Program Act, 119th Congress (2025): per-patient/episode-based, site-neutral payment. https://www.congress.gov/bill/119th-congress/senate-bill/1031/text (predecessor CMS RO Model never implemented ⟳). ↩

  15. Radiation oncology lifestyle & wellbeing digest (mid-2026) — ~45–50 hrs/week, outpatient/scheduled, minimal phone-based call, continuity trade-off, lower-end burnout with the "oncology"-category data caveat, career longevity into 60s, and job-market anxiety as the signature structural stressor. Corrected 2026-08-17: this list included "~90% would-choose-again / ~3.9/5 satisfaction" as claims the digest supports, which the Wellbeing section had already withdrawn in as many words. A footnote listing what a source supports cannot keep asserting a figure the page has retracted; both are struck here and the retraction stands as the page's position. SalaryDr (2026, https://www.salarydr.com/specialty/radiation-oncology); AMA/Rege profile (https://www.ama-assn.org/medical-students/preparing-residency/what-it-s-specialize-radiation-oncology-shadowing-dr-rege). SalaryDr panel size: n=42. A self-selected physician panel; the n is disclosed here because it is what the figure rests on. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  16. Medscape Physician Lifestyle / Burnout & Depression Report 2024 (all-physician burnout ~49%; rad onc frequently folded into "oncology" ~49–53%, not always broken out) and Physician Mental Health & Wellbeing 2025. ⟳ https://www.medscape.com/sites/public/lifestyle/2024 ; https://www.medscape.com/sites/public/mental-health/2025 ; Healthgrades summary: https://resources.healthgrades.com/pro/the-most-and-least-burned-out-physicians-by-specialty ↩

  17. Women in rad onc — active physicians 27.1% (AAMC 2016 baseline, via Becker's, https://www.beckersasc.com/gastroenterology-and-endoscopy/gender-breakdown-of-active-physicians-in-36-specialties/, current share likely higher ⟳); residents 37.5% women in academic year 2024-25 (ACGME, Data Resource Book, Academic Year 2024-2025, Table C.21, https://www.acgme.org/globalassets/pfassets/publicationsbooks/2024-2025_acgme_databook_document.pdf), up from ~31% in a ~2018–19 cohort rising ~0.9–1.5 pts/yr (IUPUI ScholarWorks study, https://scholarworks.indianapolis.iu.edu/items/73d97fe3-7012-473d-aca2-82e2b7d4b611/full); academic full-time female faculty ~30% (FREIDA/AMA, https://freida.ama-assn.org/specialty/radiation-oncology). All-specialty ~38% women: AAMC. Correction 2026-08-13: this page previously carried "~31%+ residents" in the Quick dashboard and projected a "likely mid-30s%" current share in Who's in the field. The ACGME book publishes the current count and it is 37.5%. ↩

  18. ASTRO, 2024 Member Survey Results (2025) — ~33% female membership / 29% female survey respondents; White predominant followed by Asian; ~20% of respondents Hispanic/Latino/Spanish origin (respondents, not full workforce). https://www.astro.org/news-and-publications/astronews/2025/winter-astronews/society/2024-member-survey-results ↩ ↩2

  19. AAMC, 2025 Key Findings — Physician Workforce (2025); rad onc not among top-female specialties (highest peds 66.7%, OB/GYN 64.1%), confirming it remains well below the median female share. https://www.aamc.org/data-reports/data/2025-key-findings ↩

  20. Aggregator context on applicant-to-position ratio and DO-friendliness (~0.56 US MD-senior applicants/position; DO historically "not friendly"). ProspectiveDoctor, "How Competitive is a Radiation Oncology Residency?" (2025, aggregator — treat as ⟳): https://www.prospectivedoctor.com/how-competitive-is-a-radiation-oncology-residency/ ↩

  21. ASTRO/SCAROP/ADROP/ARRO collaboration on URiM underrepresentation and the potential impact of ending affirmative action on the rad-onc pipeline; specialty-specific URiM percentages: limited data, ⟳ against AAMC Diversity in Medicine / ACGME. Int J Radiat Oncol Biol Phys (2024): https://www.sciencedirect.com/science/article/abs/pii/S0360301624007478 ↩

  22. Mudit Chowdhary, MD — KevinMD, "Radiation oncologists aren't just strangers in the basement" (2019). https://www.kevinmd.com/2019/02/radiation-oncologists-arent-just-strangers-in-the-basement.html ↩ ↩2 ↩3

  23. Simul Parikh — "The Future of Radiation Oncology," Radiation Medicine: Dollars and Sense (Substack, 2024) — contrarian workforce/economics case: supply +16% vs incidence +4% (2015–2023); projected ~10–15% real income decline over 5 yrs; still encourages entry for intrinsic rewards. https://radiationeconomics.substack.com/p/the-future-of-radiation-oncology ↩ ↩2

  24. ASTRO Workforce analyses — rough supply–demand balance projected through 2030; Medicare-eligible cancer-population growth offsetting rising physician numbers; hypofractionation/loss-of-indications only moderate modeling effects. ASTRO Blog (2023, https://www.astro.org/blog/march-2023/balance-in-radiation-oncology-workforce-supply-and-demand-predicted-through-2030); Red Journal Workforce Taskforce review (2023, https://www.redjournal.org/article/S0360-3016(23)00207-9/fulltext). ⟳ ↩

Researched with AI assistance and reviewed by hand. How this site is made